Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Patients with BV-resistant cHL have poor outcomes. These data serve as a reference for newer agents active in BV-resistant disease

from Cancer via ola Kala on Inoreader http://ift.tt/1QjajFL
via IFTTT